Taxol

SKU: orb1310120

Description

Paclitaxel is a natural, microtubule-stabilizing compound with potent anti-tumor activity. It induces cell death through mitotic arrest, apoptosis, and autophagy, making it a critical tool for cancer research in both in vitro cell studies and in vivo xenograft models.

Research Area

Cell Biology

Key Properties

• CAS Number: 33069-62-4
• MW: 853.9
• Purity: >98%
• Formula: C₄₇H₅₁NO₁₄
• SMILES: CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1
• Target: Cytoskeleton
• Solubility: Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 20 mg/ml)

Bioactivity

• Target IC50:
  1A9 cells:0.002 μM|1A9/ptx-22 cells:160.7 nM|HeLa cells:0.001 μM|CCRF-HSB-2 cells:0.25 µM|A431 cells:0.001 μM|B16 cells:0.04 μM|1A9/ptx-10 cells:157 nM|A375 cells:0.002 μM|4T1 cells:0.001 mM|C6 cells:3.1 nM|Microtubule:4 nM|184B5 cells:2.32 μM|143B cells:5.56 μM|769-P cells:7.1 μM|A121 cells:6.1 nM
• In Vivo:
  METHODS: To investigate the effect of low-dose Paclitaxel on tumor invasion, Paclitaxel (2.6 mg/kg) was administered intraperitoneally to SCID mice bearing cholangiocarcinoma tumor EGI-1 once daily for two weeks. RESULTS: Low-dose Paclitaxel treatment reduced the pulmonary spread of EGI-1 cells without significantly affecting their local tumor growth. METHODS: To develop a preclinical model of Paclitaxel alcohol-induced negative affective symptoms, Paclitaxel (2-8 mg/kg in 1 volume ethanol+1 volume Emulphor-620 +18 volumes distilled water) was injected intraperitoneally into C57BL/6J mice every four injections were given to C57BL/6J mice once every two days. RESULTS: 8 mg/kg Paclitaxel treatment resulted in the development and maintenance of mechanical and cold abnormalities of pain. Paclitaxel also induced anxiety-like and depressive-like behaviors. Paclitaxel produced behavioral changes in the mouse affective state modeling assay, whereas the increase in injurious responses lasted longer.
• In Vitro:
  METHODS: Human T-cell lymphoblastic leukemia cells CCRF-HSB-2 were treated with Paclitaxel (0.01-1 µM) for 48 h. Cell growth inhibition was detected by MTT. RESULTS: Paclitaxel dose-dependently inhibited the growth of CCRF-HSB-2 cells with an IC50 of 0.25 µM. METHODS: Human gastric cancer cells AGS were treated with Paclitaxel (10-160 nM) for 24-48 h. The expression levels of target proteins were detected by Western Blot. RESULTS: Paclitaxel induced the up-regulation of the expression of cleaved caspase-3 and cleaved PARP, which are apoptosis-related proteins. METHODS: Canine mammary tumor cells CHMm were treated with Paclitaxel (0.01-1 μM) for 24 h. Apoptosis was detected using Flow Cytometry. RESULTS: Paclitaxel dose-dependently induced apoptosis in CHMm cells.
• Cell Research:
  1×10^4 cells are plated in 100 μL of the growth medium in the presence or absence of increasing concentrations (0.1-1 μM) of taxol in 96-well plates and cultured at 37°C in 5% CO2 for 12-48 h. The cells are then incubated with 25 μL of MTT (5 mg/mL) at 37°C for 4 h. After dissolving the crystals with 0.04 N HCl in isopropanol, the plates are read in a microplate reader at 570 nm .
• Animal Research:
  Adult (250-320 g) male Sprague-Dawley rats are used for all experiments. One week following the DiI injection, rats are anesthetized with isofluorane and injected into the tail vein with 2 mg/kg paclitaxel or its vehicle (1:1:23, cremophor EL:ethanol:0.9% saline). The tail vein injection is repeated three more times every other day for a total of four injections .

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Paclitaxel; NSC125973

Compound Identifiers

PubChem CID

36314